ZLAB
NASDAQ
$20.52
Zai Lab Ltd (ZLAB)
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $33.30 (+62.28%)
Market Cap
$2.27B
Revenue 5Y CAGR
+49.02%
Free Cash Flow Yield
-4.79%
Beta (5Y)
0.91
Price Chart
Valuation
Market Cap$2.27B
P/S4.96
P/B3.29
Profitability
Total Revenue (TTM)$447M
Gross Profit (TTM)$37M
EBITDA-$227M
Profit Margin-53.4%
Operating Margin-72.6%
EPS-$1.61
Financial Health
Debt-to-Equity32.3%
Free Cash Flow Yield-4.79%
Growth & Risk
Revenue 5Y CAGR+49.02%
FCF 5Y CAGR-21.13%
Beta (5Y)0.91
Sharpe Ratio-0.90